ClinicalTrials.gg
RecruitingNCT06909253MG-ARCADIAUpdated Nov 20, 2026

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

An observational study in Myasthenia Gravis, Generalized, sponsored by AstraZeneca. Recruiting at 11 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by AstraZeneca · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Myasthenia Gravis by AstraZeneca — 8 open to participants now, 11 under way, 4 of them phase 3. Myasthenia Gravis · AstraZeneca.

Started
2025
with 3 others
Observational
6 of 19
5 open now
Primary completion
2029-12
later than 8 of 10 live
Registered
15th of 19
by date

Among the 19 studies in Myasthenia Gravis by AstraZeneca, this one is one of 4 that started in 2025, is one of 6 observational ones, reaches primary completion later than 8 of the 10 other live ones, and was the 15th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

8 of the 19 studies in Myasthenia Gravis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Myasthenia Gravis by AstraZeneca, or all of them as a file.
02

Study summary

The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.

Read the detailed description

The Polish, prospective, multicenter, observational, cohort study designed to collect longitudinal data on the management and clinical outcomes of patients with gMG naive to complement inhibitors who received ravulizumab in the scope of routine clinical practice within the frames of National Drug Program (NDP) for up to 42 months (\~ 6 months baseline and \~36 months follow-up).

03

Conditions studied

  • Myasthenia Gravis, Generalized

Browse trials for

Keywords

  • Ravulizumab
  • Generalized Myasthenia Gravis
  • gMG
  • observational
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult (aged ≥18 years) patients with gMG, naive to complement inhibitors, receiving ravulizumab treatment within the frames of NDP in Poland.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (aged ≥18 years) patients with gMG, naive to complement inhibitors, receiving ravulizumab treatment in the frames of NDP in Poland.
  • Patients willing to participate in the study and signed Form (ICF).
  • Vaccination against N. meningitidis

Exclusion criteria

Exclusion Criteria:

  • Those who plan to participate in gMG clinical trial on/after the date of first ravulizumab infusion through NDP.
  • Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Ravulizumab

    Open-lable arm with gMG patients who received ravulizumab treatment in the frames of NDP in Poland.

    Drug: Ravulizumab

Interventions

  • Ravulizumab, concentrate for solution for infusion

    Also known as: Ultomiris

06

What researchers measure

Primary outcomes

  1. Change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score

    Time frame: at 6 month

Secondary outcomes

  1. Change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score

    Time frame: at month 12, 24, 36

  2. Change from baseline in MG-ADL subcomponent scores

    Subcomponent scores - bulbar, limbs, respiratory, and ocular

    Time frame: at month 6, 12, 24, 36

  3. Change from baseline in Myasthenia Gravis (MG) composite scale

    Time frame: at month 6, 12, 24, 36

  4. Proportion of patients who achieved response

    Response - an improvement of ≥ 2 points in MG-ADL total score (proportion of patients with ≥ 3 improvement will be also presented)

    Time frame: at month 6, 12, 24, 36

  5. Change in the Revised 15-Component Myasthenia Gravis Quality of Life (MG-QOL15r) score

    Time frame: at month 6, 12, 24, 36

  6. Change from baseline in Work Productivity and Activity Impairment: Specific Health Problem (WPAI:SHP)

    Time frame: at month 6, 12, 24, 36

  7. Change from baseline in Patient Global Impression of Change (PGI-C)

    Time frame: at month 6, 12, 24, 36

  8. Change from baseline in Neuro-Qol Short Form v1.0 - Fatigue

    Time frame: at month 6, 12, 24, 36

  9. Change from baseline in Patient Health Questionnaire - 9 (PHQ-9)

    Time frame: at month 6, 12, 24, 36

07

Study locations

10 of 11 sites recruiting
  • Research Site
    Bydgoszcz, Poland
    Recruiting
  • Research Site
    Gdansk, Poland
    Recruiting
  • Research Site
    Katowice, Poland
    Recruiting
  • Research Site
    Krakow, Poland
    Recruiting
  • Research Site
    L DZ, Poland
    Recruiting
  • Research Site
    Lublin, Poland
    Recruiting
  • Research Site
    Poznan, Poland
    Recruiting
  • Research Site
    Szczecin, Poland
    Recruiting
  • Research Site
    Szczecin, Poland
    Withdrawn

    Not enrolling at this site.

  • Research Site
    Warsaw, Poland
    Recruiting
  • Research Site
    Wroclaw, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2029, 55 months after the start.

Of 62 observational studies under Myasthenia Gravis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 24. This study's planned 55 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2025
First posted
Apr 3, 2025
StartActual
May 15, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06909253
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 3, 2025
Start date
May 15, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion